The proteasome inhibitor bortezomib can downregulate HLA-E, the ligand for the inhibitory NKG2A receptor, and increase surface expression of death receptors on cancer cells to promote NK cell cytotoxicity against multiple myeloma cells [33]. Here, HLA-E is linked to plasma cell myeloma.